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Hepatocellular Carcinoma Xenografts 
Established From Needle Biopsies Preserve 
the Characteristics of the Originating 
Tumors
Tanja Blumer,1* Isabel Fofana,1* Matthias S. Matter,2 Xueya Wang,1 Hesam Montazeri,2,3 Diego Calabrese,1 Mairene Coto-Llerena,1 
Tujana Boldanova,1,4 Sandro Nuciforo,1 Venkatesh Kancherla,2 Luigi Tornillo,2 Salvatore Piscuoglio ,2,5 Stefan Wieland,1  
Luigi M. Terracciano,2 Charlotte K.Y. Ng,1,2,6 and Markus H. Heim1,4
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Treatment options 
for patients with advanced-stage disease are limited. A major obstacle in drug development is the lack of an in vivo 
model that accurately ref lects the broad spectrum of human HCC. Patient-derived xenograft (PDX) tumor mouse 
models could overcome the limitations of cancer cell lines. PDX tumors maintain the genetic and histologic het-
erogeneity of the originating tumors and are used for preclinical drug development in various cancers. Controversy 
 exists about their genetic and molecular stability through serial passaging in mice. We aimed to establish PDX mod-
els from human HCC biopsies and to characterize their histologic and molecular stability during serial passaging. A 
total of 54 human HCC needle biopsies that were derived from patients with various underlying liver diseases and 
tumor stages were transplanted subcutaneously into immunodeficient, nonobese, diabetic/severe combined immuno-
deficiency gamma-c mice; 11 successfully engrafted. All successfully transplanted HCCs were Edmondson grade III 
or IV. HCC PDX tumors retained the histopathologic, transcriptomic, and genomic characteristics of the original 
HCC biopsies over 6 generations of retransplantation. These characteristics included Edmondson grade, expression 
of tumor markers, tumor gene signature, tumor-associated mutations, and copy number alterations. Conclusion: PDX 
mouse models can be established from undifferentiated HCCs, with an overall success rate of approximately 20%. 
The transplanted tumors represent the entire spectrum of the molecular landscape of HCCs and preserve the char-
acteristics of the originating tumors through serial passaging. HCC PDX models are a promising tool for preclinical 
personalized drug development. (Hepatology Communications 2019;3:971-986).
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the sec-ond most frequent cause of cancer-related 
mortality worldwide.(1) Current treatment options are 
limited, with less than 30% of patients with HCC in 
Europe qualifying for curative treatments.(2) Sorafenib 
and lenvatinib are the only first-line treatments for 
advanced HCC.(3,4) These drugs moderately improve 
Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CD, clusters of differentiation; CNA, copy number alternation; 
EBV, Epstein-Barr virus; H&E, hematoxylin and eosin; HCC, hepatocellular carcinoma; ID, identification number; PDX, patient-derived 
xenograft; PDX-1/6, patient-derived xenograft first/sixth generation; TCGA, The Cancer Genome Atlas; WES, whole-exome sequencing.
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survival of patients with advanced HCC but have 
adverse effects that preclude their use in patients with 
advanced cirrhosis.(3-5) Novel therapies are urgently 
needed to improve treatment options for patients with 
advanced HCCs.
Current in vitro cell culture models of HCC are 
based on conventional hepatoma cell lines that fail 
to recapitulate key features of tumor tissues, such as 
three-dimensional tumor architecture, cellular hetero-
geneity, and cell–cell interactions. Chemically induced 
HCC mouse models or genetically engineered mice 
better reflect in vivo tumor biology(6); however, they 
do not recapitulate the different genetic alterations 
present in HCCs of different patients. Patient-derived 
xenograft (PDX) models have the potential to over-
come these limitations and are considered valuable 
tools in the field of anticancer drug development and 
prediction of response to cancer therapy.(7,8) However, 
a recent publication described widespread mouse- 
specific tumor evolution and seriously challenged the 
usefulness of serially passaged PDXs.(9) The authors 
analyzed more than 1,000 PDX samples across 24 
cancer types and observed rapid accumulation of copy 
number alterations (CNAs) during PDX passaging.(9) 
However, the available data on liver cancers were very 
limited.(9) Another limitation of the published HCC 
PDX models is that all of these have been generated 
from surgically resected HCCs.(10-15) Because surgical 
resections are predominantly performed in patients 
with early stage tumors (typically Barcelona Clinic 
Liver Cancer [BCLC] stages 0/A), PDXs derived 
from resected tumors are heavily biased against 
advanced-stage HCCs. Furthermore, from the pub-
lished HCC PDX reports, it is not clear how much of 
the original tumor characteristics are preserved in the 
transplanted tumors. It is also not clear if successful 
engraftment is restricted to a subgroup of HCCs with 
specific molecular characteristics. These questions 
need to be resolved before further developing PDX 
models for preclinical drug development.
In the present study, we report the results of a com-
prehensive comparative analysis at the histopathologic, 
transcriptomic, and genomic levels of 11 newly gener-
ated PDX models serially passaged over 6 generations 
and the originating human HCCs.
Materials and Methods
Human HCC tissues anD 
Biopsy pRoCeDuRe
A total of 54 human HCC needle biopsies were 
obtained at the University Hospital Basel, Basel, 
Switzerland, from 44 patients who were treat-
ment naive and undergoing diagnostic liver biopsy 
(Supporting Table S1; Supporting Methods). Written 
informed consent was obtained from all patients. The 
study was approved by the ethics committee of the 
northwestern part of Switzerland (protocol #EKNZ 
2014-099). One biopsy cylinder was formalin fixed 
and paraffin embedded for diagnosis and staging. 
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Additional cylinders were immediately snap frozen 
in liquid nitrogen for later use in DNA/RNA extraction 
or embedded in O.C.T. compound (Tissue-Tek) and 
frozen using standard procedures. For PDX model gene- 
ration, biopsy pieces were placed in phosphate- 
buffered saline. An additional biopsy from nontumor 
liver parenchyma was also obtained from all patients.
miCe anD 
XenotRansplantation
HCC needle biopsies were transplanted subcuta-
neously into 6- to 10-week-old, nonobese, diabetic/
severe combined immunodeficiency gamma-c mice 
(Supporting Methods). Experiments were conducted 
with the approval of the ethics committee of the 
northwestern part of Switzerland (protocol #EKNZ 
2014-099) and the animal care committee of Canton 
Basel-Stadt, Switzerland.
Histology anD 
immunoHistoCHemistRy
Paraffin-embedded tumor biopsies and PDX tumors 
were processed for hematoxylin and eosin (H&E) or 
immunohistochemical staining using standard proce-
dures (Supporting Methods). Histopathology evaluation 
was carried out blindly by two board-certified hepatopa-
thologists (Dr. Luigi Tornillo and Dr. Matthias S. Matter) 
at the Institute of Pathology of the University Hospital 
Basel. Disease stage and histopathologic grading were 
classified according to the BCLC staging system(16) and 
the Edmondson grading system,(17) respectively.
Rna seQuenCing anD analysis
Total RNA was extracted from 45 HCC biopsies 
derived from 37 patients (Supporting Table S2), from 
16 first-, 8 fourth- and 20 sixth-generation HCC 
PDX tumors and 3 first-generation lymphoma PDX 
tumors. All RNA samples were sequenced on an 
Illumina HiSeq 2500 system (Supporting Methods).
Sequence reads were aligned by STAR (version 
2.5.2a)(18) (Supporting Methods). Transcript quan-
tification for human genes was performed using 
RSEM (version 1.2.31),(19) differential expres-
sion analysis using the edgeR R package (version 
3.18.1),(20) pathway enrichment analyses using the 
hypergeometric test, and single-sample gene set 
enrichment analysis(21) using the GSVA package 
(version 1.24.2)(22) for the hallmark gene sets in the 
Molecular Signatures Database.(23) Cluster analysis 
was performed using hierarchical clustering. Batch 
effects associated with the xenografting process were 
removed using a linear model(20) prior to clustering. 
The expression of somatic mutations in the RNA 
sequencing data was determined by GATK Unified 
Genotyper,(24) given the somatic mutations identi-
fied in HCC biopsies by whole-exome sequencing 
(WES). For statistical comparisons, only missense 
and synonymous mutations were considered because 
truncating, insertions, and deletions and splice site 
mutations are likely to affect transcript stability. 
CNA profiles were derived with the CNVkit (ver-
sion 0.9.5)(25) using 15 unrelated normal livers as 
control. Correlation between samples was calcu-
lated as the Spearman’s rho of the gene-level seg-
mented log2 ratio. Transcriptomic classification 
was performed according to Hoshida et al.(26) (see 
Supporting Methods for further details).
Wes anD analysis
Paired-end 101-base pair sequencing was per-
formed for the DNA extracted from 14 engrafted 
HCC biopsies (derived from 12 patients) and the 
12 matched nontumoral biopsies (Supporting Table 
S2) using the SureSelectXT Clinical Research Exome 
(Agilent) platform and the Illumina HiSeq  2500 
according to the manufacturers’ guidelines. WES 
data were analyzed essentially as described(27) 
(Supporting Methods).
tHe CanCeR genome atlas 
Data analysis
The Cancer Genome Atlas (TCGA) HCC RNA 
sequencing data retrieved from the Genomics Data 
Commons(28) were merged with the RNA sequenc-
ing data of our cohort for clustering (Supporting 
Methods). Histologic grading was performed 
according to the Edmondson grading system(17) as 
described(29) (Supporting Methods).
Data aVailaBility
Sequencing data are available at the European 
Genome-phenome Archive under accession 
EGAS00001003396.
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Results
FResH Human HCC neeDle 
Biopsies geneRate 
XenogRaFt tumoRs in 
immunoCompRomiseD miCe
PDX models were generated from human HCC 
needle biopsies as described in Materials and Methods. 
A total of 54 needle biopsies from 44 patients with 
HCC were included in this study (Supporting Tables 
S1 and S2). The patient cohort covered all major HCC 
risk factors and the entire spectrum of Edmondson 
grades (I-IV)(17) (Supporting Table S1). Additionally, 
in contrast to the use of resected HCC tissue, which is 
limited to early stage disease,(11,14,15) our cohort com-
prised all four classes of the BCLC staging system.(16)  
Although we typically obtained a single biopsy sample per 
patient, there were 9 patients that were simultaneously 
biopsied at two locations because of the presence of 
multiple lesions in the liver (Supporting Table S1). One 
patient was biopsied at two different locations within 
the same large tumor nodule (Supporting Table S1). 
In total, we successfully established 11 HCC-derived 
PDX models from 10 patients (Supporting Table S1).
The time from subcutaneous introduction of the 
HCC biopsy material to onset of tumor growth ranged 
from 4 to 28  weeks (Fig. 1A,B). Time to onset of 
PDX tumor growth of Edmondson grade IV-derived 
biopsies appeared to be shorter than that of grade 
III biopsies, but the difference did not reach statis-
tical significance (P  = 0.072; Mann-Whitney U test) 
(Fig. 1). Interestingly, PDX C078b derived from sub-
cutaneous injection of a biopsy cell suspension showed 
the latest tumor growth onset (Fig. 1A,B), suggest-
ing that the presence of an intact tumor architecture 
may accelerate tumor engraftment and growth onset. 
Finally, the onset of tumor growth varied between 
mice that received a transplant with tumor tissue 
derived from the same biopsy cylinder (Supporting 
Fig. S1A), suggesting that, among other factors, the 
tumor cell content may also influence the lag time to 
tumor growth. Indeed, the lag time to tumor growth 
was similar when a homogeneous cell suspension gen-
erated from one biopsy cylinder was subcutaneously 
injected into two mice (Supporting Fig. S1B).
Taken together, these results demonstrate that 
human HCC tissue derived from fresh needle biopsies 
can generate xenografts following subcutaneous trans-
plantation and injection.
gRoWtH KinetiCs oF HCC 
XenogRaFt tumoRs Remain 
staBle oVeR suBseQuent 
passages
Having successfully established 11 PDX models, we 
next investigated the retransplantation capacity of the 
initial xenografts over at least 6 generations. Retrans- 
planted tumors showed a shortened lag phase until 
onset of tumor growth compared to the xenograft 
tumor derived from the biopsy tissue and remained 
stable in subsequent PDX generations (Fig. 1B,C). The 
doubling time of tumor growth differed between PDX 
models. There were three models (C677, C798, D135) 
with a >20% shorter and one model (C078b) with a >20% 
longer doubling time in one or more of the subsequent 
generations compared with the first generation. In the 
other seven models, growth rates remained stable among 
generations (Fig. 1B,C). Furthermore, Ki-67 staining 
of first- and fourth-generation PDX tumors showed 
similar proliferation rates (Supporting Fig. S2). Taken 
together, these data indicate that, once established, 
PDX tumors can be expanded for several generations 
with reasonable stable growth kinetics over time.
pDX tumoRs ReCapitulate 
tHe HistopatHologiC 
FeatuRes oF tHe oRiginal 
Human HCC tumoRs
We next investigated whether the individual PDX 
tumors retained the histologic characteristics of the 
original human tumors. HCC PDX tumors maintained 
the differentiation grade,(17) growth pattern, and cyto-
logic subtype(30,31) of the originating human HCC 
biopsies over at least 4 generations (Table 1; Fig. 2; 
Supporting Fig. S3A-J). As an example, the PDX 
tumors originating from tumor biopsy C942 displayed 
a solid-trabecular growth pattern with an Edmondson 
grade III, as observed in the original tumor (Fig. 2; 
Table 1). Of note, only in one case (PDX model 
C284b) did we observe the loss of the trabecular aspect 
of the growth pattern that was present in the original 
biopsy; however, the solid growth pattern and dif-
ferentiation grade were maintained over subsequent 
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passages from mouse to mouse (Table 1; Supporting 
Fig. S3B).
Immunohistochemical analysis demonstrated that 
the expression and distribution of the tumoral marker 
alpha-fetoprotein (AFP)(32) were maintained from the 
original tumor biopsies to the HCC xenografts over 
several generations (Fig. 2; Supporting Fig. S3A-J). 
Likewise, the expression pattern of the three most widely 
used markers for HCC diagnosis,(33,34) glypican 3, heat 
shock protein 70, and glutamine-synthetase, confirmed 
the histologic stability of the xenograft tumors com-
pared to the original HCC biopsy (Fig. 2; Supporting 
Fig. S3A-J). Taken together, these results show that 
the HCC PDX tumors retain the histologic features 
of the original human tumors through serial passaging.
pDX tumoRs ReCapitulate 
tHe tRansCRiptomiC pRoFile 
oF tHe oRiginal Human HCC 
tumoRs
To investigate the transcriptomic changes induced 
by PDX establishment and whether the PDX models 
recapitulate the gene expression pattern of the tumors 
from which they originated, we performed RNA 
sequencing of all PDX models at multiple time points 
(Supporting Fig. S4) and of the originating HCC 
biopsies. Differential expression analysis revealed 
that 2,102 genes were up-regulated and 3,576 genes 
were down-regulated in the PDX tumors (first gen-
eration) compared to their matched biopsies (Fig. 3A; 
Supporting Table S3). Compared to the HCC tumors, 
first-generation PDX tumors showed down-regulation 
of pathways of inflammatory response and angio- 
genesis (Fig. 3B; Supporting Table S4), suggesting the 
loss of cells of the human immune system and vas-
culature. Indeed, the xenograft tumors were positive 
for mouse-specific clusters of differentiation (CD)31, 
suggesting that the human vascular system in the 
HCC tumors was replaced by mouse vessels in the 
xenografts (Supporting Fig. S5). In contrast, pathways 
related to the cell cycle, such as Myc and E2F target 
genes and mammalian target of rapamycin complex C1 
signaling, were up-regulated in PDX tumors (Fig. 3B; 
Supporting Table S4), likely reflecting the enrichment 
of tumor cells in the PDX tumors compared to the 
Fig. 1. Xenograft tumor growth patterns. (A) Lag phase and tumor growth rate of first-generation xenografts. Edmondson grades 
III and IV are shown in green and red, respectively. Circles and diamonds represent transplanted solid pieces and cell suspensions, 
respectively. (B) Growth characteristics of PDX models. Lag phase until detectable tumor formation, doubling time of tumors from 
first-, second-, third-, and fourth-generation PDX tumors and number of transplanted tumors are indicated. Results are shown as 
mean ± SD. (C) Tumor growth rate over several generations (first to fourth) in one representative PDX model (C284b). Transplantation 
generations are color coded.
taBle 1. eDmonDson gRaDe, gRoWtH patteRn, anD CytologiC suBtype oF Biopsies anD 
CoRResponDing pDX tumoRs
Biopsy ID
Edmondson Grade Growth Pattern Cytologic Subtype
Biopsy PDX-1 PDX-4 Biopsy PDX-1 PDX-4 Biopsy PDX-1 PDX-4
C078b III III III Solid Solid Solid - - -
C284b III III III Solid-trabecular Solid Solid - - -
C677 IV IV IV Solid Solid Solid Giant cells Giant cells Giant cells
C678 IV IV IV Solid Solid Solid Giant cells Giant cells Giant cells
C798 III III III Solid-trabecular Solid-trabecular Solid-trabecular - - -
C942 III III III Solid-trabecular Solid-trabecular Solid-trabecular - - -
C949 III III III Solid-trabecular Solid-trabecular Solid-trabecular - - -
C965 III III III Solid Solid Solid - - -
C975 III III III Solid Solid Solid - - -
D096 IV IV IV Solid Solid Solid - - -
D135 IV IV IV Solid-trabecular Solid-trabecular Solid-trabecular Clear cell, 
giant cells
Clear cell, 
giant cells
Clear cell, 
giant cells
Abbreviation: PDX-4, fourth-generation tumor.
Hepatology CommuniCations, Vol. 3, no. 7, 2019 BLUMER, FOFANA, ET AL.
977
biopsies. Importantly, unsupervised clustering after 
correcting for the systematic effects introduced by 
xenografting using a linear model demonstrated that 
first-generation PDX tumors stably clustered with 
their corresponding HCC tumors (Fig. 3C; stability 
as assessed by bootstrap resampling), suggesting that, 
aside from the loss of the human immune and vas-
culature systems, the PDX tumors maintained the 
tumor-specific transcriptomic features of their origi-
nating tumors. By contrast, gene expression over PDX 
generations remained markedly stable, with only three 
and 43 up- or down-regulated genes, respectively, 
Fig. 2. HCC PDX mice recapitulate the histologic characteristics as well as the expression patterns of HCC markers of the original 
tumor. Histologic sections of the original HCC biopsies and their derivative PDX tumors (PDX-1 and PDX-4) stained with H&E for 
AFP expression as well as GPC3, HSP70, and GS detected by immunohistochemistry. Scale bar, 200 μm. Representative stainings 
are shown for PDX model C942. Abbreviations: GPC3, glypican 3; GS, glutamine synthetase; HSP70, heat shock protein 70; PDX-1, 
first-generation PDX; PDX-4, fourth-generation PDX.
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978
Hepatology CommuniCations, Vol. 3, no. 7, 2019 BLUMER, FOFANA, ET AL.
979
between the first- and sixth-generation PDX tumors 
(Fig. 3A,B), and the expression profile was maintained 
over at least 6 generations (Fig. 3D; Supporting Fig. S6A). 
Taken together, these data indicate that the PDX 
tumors recapitulate the transcriptomic features of the 
original HCC biopsies over several generations.
pDX tumoRs Retain tHe 
genomiC CHaRaCteRistiCs oF 
tHe oRiginal HCC tumoRs
To assess whether the PDX tumors retained the 
expression of the somatic mutations found in their 
originating tumors, we identified the repertoire of 
somatic mutations by performing WES of the origi-
nal tumor biopsies and their nontumoral counterparts. 
We then assessed the expression of these somatic 
mutations by RNA sequencing in the HCC biopsies 
and the PDX tumors, focusing on missense and syn-
onymous point mutations because truncating muta-
tions are likely to affect transcript stability. Based on 
WES, we identified a median of 121 (range, 49-8,015) 
somatic missense and synonymous point mutations, of 
which 40% (range, 33%-48%) were expressed in the 
corresponding HCC biopsies (Supporting Table S5). 
Of the expressed mutations in the HCC biopsies, a 
median of 85% (range, 65%-100%) was also expressed 
in the respective PDX tumors (Fig. 4A). Importantly, 
all missense mutations in HCC cancer genes, such as 
tumor protein p53 (TP53), catenin beta 1 (CTNNB1), 
albumin (ALB), and lysine methyltransferase 2B 
(KMT2B), were expressed in the corresponding PDX 
tumors, and their expression was maintained over at 
least 6 generations (Fig. 4A; Supporting Fig. S6B).
The overall pattern of CNAs remained largely 
similar between the original HCC biopsies and 
the corresponding PDX tumors (Fig. 4B,C). CNAs 
were found in only two cases. In HCC biopsy 
C942, copy number gain of chromosome 8q found 
in the HCC biopsy was observed in the deriva-
tive first/sixth(b)-generation PDX but not in first/
sixth(a)-generation PDX, whereas first/sixth(a)- 
generation PDX but not first/sixth(b)-generation PDX 
acquired copy number loss of chromosome 4q (Fig. 4B; 
Supporting Fig. S7A). In C975, copy number gain 
of chromosome 1q was not seen in the PDX tumors 
(Fig. 4B). Of note, there were no significant changes 
in CNAs throughout the first- to sixth-generation 
tumors (Fig. 4; Supporting Fig. S7), demonstrating 
genomic stability over several generations.
Taken together, these results demonstrate that the 
PDX tumors largely maintain the mutational land-
scape and genetic alterations observed in their orig-
inating tumors. Importantly, genomic stability was 
observed over at least 6 PDX generations.
engRaFteD HCC Biopsies aRe 
BRoaDly RepResentatiVe 
oF tHe speCtRum oF pooRly 
DiFFeRentiateD HCCs
The success rate of engraftment was 20% (10/50 
biopsies) and 25% (1/4 biopsies) of all transplanted 
and injected biopsy tissues, respectively (Supporting 
Table S1). This success rate is in accordance with 
published data on subcutaneously injected PDX mod-
els derived from resected specimens.(11,13-15) The use 
of HCC needle biopsies that encompass all clinical 
stages offered the unique opportunity to investigate the 
determinants of successful engraftment capacity into 
mice. When we compared the clinicopathologic char-
acteristics of the engrafted and nonengrafted biopsies, 
we observed a clear correlation with histopathologic 
grading; all HCC PDX tumors were derived from 
poorly differentiated tumors (Edmondson grades III/
IV) (Fig. 5A; Supporting Table S1). Indeed, differen-
tial expression analysis between engrafted and non-
engrafted biopsies revealed 2,401 up-regulated and 
Fig. 3. HCC PDX mice recapitulate the transcriptomic features of their original tumors. (A) Venn diagrams illustrate the number 
of up- and down-regulated genes between HCC biopsies and the first-generation PDX tumors and between the first- and sixth-
generation PDX tumors. (B) Box plots of gene set enrichment scores from selected pathways differentially expressed between HCC 
biopsies and first-generation PDX tumors across all biopsies and PDX tumors. Each dot represents the enrichment score from single-
sample Gene Set Enrichment Analysis of a given pathway in a given sample. The boxes represent the first and third quartile with 
the line representing the median. The whiskers extend to 1.5 times the length of the box. *: P < 0.05; **: P < 0.01; ****: P < 0.0001. 
(C) Unsupervised clustering of HCC biopsies and first-generation PDX tumors, corrected for systemic biases between the two groups. 
(D) Unsupervised clustering of first- and sixth-generation PDX tumors. Abbreviations: IL6, interleukin-6; JAK-STAT3, Janus kinase-
signal transducer and activator of transcription 3; NS, not significant.
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1,440 down-regulated genes. The up-regulated genes 
were enriched for pathways associated with cell-cycle 
progression, epithelial-to-mesenchymal transition, 
hypoxia, and angiogenesis, whereas the down- 
regulated genes were enriched for liver metabolic 
functions (Supporting Table S6). Furthermore, molec-
ular subtyping based on Hoshida subclasses(26) revealed 
that all engrafted HCC biopsies were subclasses 
S1 and S2 (Fig. 5A), characterized by poor differentiation, 
high proliferation rate, and poor survival compared 
to subclass S3. Besides Edmondson grading, no other 
available clinicopathologic characteristics seemed to 
influence the engraftment success rate (Supporting 
Table S1; Fig. 5A). When restricting the differential 
expression analysis to Edmondson grade III biopsies 
(the only histologic grade that had a variable success-
ful engraftment rate), only two genes were differen-
tially expressed (false discovery rate for both, 0.04; 
data not shown), suggesting that there was no system-
atic difference between engrafted and nonengrafted 
biopsies after accounting for histologic grading.
To assess the distribution of our samples within a 
reference set from TCGA,(28) we performed an unsu-
pervised hierarchical clustering analysis of the gene 
expression, combining our HCC biopsy cohort with 
TCGA.(28) We observed that the 11 engrafted biopsies 
preferentially clustered together in a subclass located at 
the left end of the clustering tree (Supporting Fig. S8). 
Because all our PDX models originated from poorly 
differentiated HCCs, we repeated the unsupervised 
clustering analysis using only the subset of poorly 
differentiated HCCs from TCGA. In this scenario, 
both the 11 engrafted samples and the nonengrafted 
samples broadly represented the spectrum of poorly 
differentiated HCCs (Fig. 5B). These results demon-
strate that poorly differentiated tumor cells engraft 
more efficiently in mice and that the HCC biopsies 
that engrafted are broadly representative of the diver-
sity of poorly differentiated HCCs.
tRansFoRmation into 
Human B-Cell lympHoiD 
neoplasms oF pDX tumoRs
During histologic analyses of the engrafted tumors, 
we observed that three PDX tumors histologically 
differed from the originating tumors. Specifically, they 
primarily contained a population of middle-sized and 
large lymphoid mononuclear cells with a diffuse growth 
pattern and high mitotic index that were not present in the 
corresponding HCC biopsies (Fig. 6A). Transcriptome-
based unsupervised clustering showed that these 
PDX tumors did not cluster with their originating 
HCCs (Fig. 6B) and did not express any of the mutations 
expressed in the corresponding biopsy (Fig. 6C; Suppo- 
rting Table S5). Compared to the biopsies and the HCC 
PDX tumors, these three PDX tumors overexpressed 
genes consistent with immune infiltration, interferon- 
alpha and gamma responses, and the nuclear factor kappa 
B pathway and reduced expression of genes involved in 
liver metabolism and liver cancer (Supporting Table S7). 
CNA analyses further confirmed that first-generation 
PDX tumors largely differed from the original HCC 
tumors (Fig. 6D). These results suggest the development 
of lymphomas in the xenografts as has been reported 
in PDX studies of various cancers.(35-38) These three 
PDX tumors stained positive for the human B-cell 
marker CD20 (Fig. 6E), consistent with the presence 
of a B-cell lymphoma. Importantly, species-specific 
alignment demonstrated that CD20 messenger RNA 
expression was exclusively of human origin (Supporting 
Table S8). Of note, Chen et al.(35) suggested that 
the reactivation of latent Epstein-Barr virus (EBV) 
of intratumoral passenger B lymphocytes led to the 
Fig. 4. HCC PDX mice recapitulate the genomic features of their original tumors. (A) The repertoire of expressed somatic missense 
mutations affecting cancer genes(28,42-44) in HCC biopsies and their corresponding PDX tumors. Nonexpressed genes and genes with 
low expression are indicated with a gray box. Multiple expressed mutations in the same gene are indicated by an asterisk. (B) Heatmap 
of copy number alterations (adjusted segmented log2 ratios) in HCC biopsies and the corresponding PDX tumors (first and sixth 
generation). Samples are presented in rows and chromosomal positions on the x axis (columns). Red, CNA gains; white, neutral; blue, 
CNA losses. (C) Box plots of the Spearman’s rho correlation coefficient between HCC biopsies and first-generation tumors, first- 
and their corresponding derivative sixth-generation tumors, and pairs of first-generation tumors. The boxes represent the first and 
third quartile with the line representing the median. The whiskers extend to 1.5 times the length of the box. Abbreviations: ALB, 
albumin; APOB, apolipoprotein B; BRCA1, breast cancer 1; CHD8, chromodomain-helicase-DNA-binding protein 8; CTNNB1, 
catenin beta-1 ; EEF1A1, eukaryotic translation elongation factor 1 alpha 1; KMT2A, lysine methyltransferase 2A; KMT2B, lysine 
methyltransferase 2B; KMT2D, lysine methyltransferase 2D;  LRP1B, low density lipoprotein receptor-related protein 1B; MGA, 
MAX dimerization protein; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase; PPM1D, protein phosphatase 1D.
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Fig. 5. Clinical, histopathologic, and molecular features of engrafted and not engrafted HCC biopsies. (A) Patient and biopsy 
characteristics of all transplanted biopsies, grouped by engraftment status. Calculations of significant differences (indicated in red) 
between engrafted versus not engrafted biopsies are shown underneath. Two-sided Fisher’s exact tests for categorical data and two-
sided Mann-Whitney U tests for ordinal data. (B) Unsupervised hierarchical clustering analysis. Biopsy (PDX) cohort (this study) 
combined with high-grade (Edmondson III to IV) HCCs from TCGA cohort. Abbreviations: ALD, alcoholic liver disease; BCLC, 
Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; MVI, 
macrovascular invasion; NAFLD, nonalcoholic fatty liver disease.
Fig. 6. Unintended lymphoid neoplasm transformation in PDX models. (A) H&E-stained sections of original HCC biopsies 
and their derivative lymphoma PDX tumors (PDX-1). (B) Unsupervised clustering of first-generation PDX and corresponding 
HCC biopsies. Lymphoma PDX tumors indicated in red. (C) Bar chart illustrating the number of expressed somatic missense and 
synonymous mutations for the nine HCC biopsies (mean) and the 10 corresponding HCC PDX tumors (mean) and for C738, C948, 
and C951 and their corresponding lymphoma PDX tumors (C738-PDX-1, C948-PDX-1, and C951-PDX-1). (D) Heatmap of copy 
number alterations (adjusted segmented log2 ratios) in HCC biopsies and their derivative lymphoma PDX tumors (first generation). 
Samples are presented in rows and chromosomal positions on the x axis (columns). Red, CNA gains; white, neutral; blue, CNA losses. 
(E) PDX tumors of the lymphoma models (C738-PDX-1, C948-PDX-1, and C951-PDX-1) stained with hCD20. Scale bar, 200 μm. 
Abbreviation: hCD20, human CD20.
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genera tion of lymphoid tumors in immunocompromised 
mice. Consistent with this hypothesis, EBV tran-
scripts were detected in all three of these PDX tumors 
but were absent from the corresponding HCC and 
nontumor biopsies and were virtually absent from all 
the other PDX models (Supporting Table S8). Taken 
together, these results suggest that reactivation of 
latent EBV may lead to lymphomagenesis in some 
cases using our biopsy-derived xenograft system.
Discussion
During the last 10 years since the introduction of 
sorafenib as a first-line therapy for advanced HCC, 
a number of additional drugs have failed in phase 2 
or phase 3 trials.(39) A major obstacle for the devel-
opment of new therapies is the lack of suitable ani-
mal models, specifically animal models that reflect 
the heterogeneity of HCCs. PDX mice derived from 
human tumors offer a tool for developing anticancer 
therapies and personalized medicine for patients with 
cancer.(8)  PDX models have also been established 
for HCCs(10-15); however, these previously published 
HCC PDX mice were established from resected 
tumor specimens and therefore predominantly from 
early stage HCCs. In the present study, we expand the 
spectrum of HCC PDX models to advanced HCCs.
As in published reports,(11,13-15) we had a limited 
overall success rate of approximately 20%. From 54 
transplanted HCCs, 11 were successfully grown and 
retransplanted as xenografts. The reasons for this 
low success rate remain to be fully elucidated; how-
ever, we observed that none of the well-differentiated 
(Edmondson grades I/II) HCCs could be engrafted 
in the mice. Of note, we stopped to monitor the 
mice for tumor growth 8 months after transplanta-
tion. Because low-grade tumors tend to grow slowly, 
we cannot exclude the possibility that they would 
have started growing beyond 8 months. However, we 
think that tumor cell intrinsic biological properties 
of undifferentiated HCCs, such as growth factor-in-
dependent proliferation or resistance to hypoxia, are 
more likely reasons for the successful engraftment of 
poorly differentiated HCCs. Another factor favor-
ing engraftment might be an intact tumor tissue 
architecture providing three-dimensional oriented 
cell–cell contacts. Compared to transplantations of 
small tumor pieces, we observed that the injection 
of a cell suspension showed a delayed tumor growth 
onset. Interestingly, time to tumor growth onset was 
invariably shorter following retransplantation of all 
PDX tumors and then remained constant over several 
passages. It is possible that the presence of a mouse- 
derived vascular system in the PDX tumors facilitated 
the accelerated engraftment following retransplanta-
tion. Once tumors started growing, most PDX models 
maintained consistent doubling time over generations, 
which may reflect the intrinsic tumor growth rate 
once a murine vasculature system is established.
The HCC biopsy-derived PDX models maintained 
a striking similarity with the original human HCCs 
with respect to differentiation grade, growth pattern, 
cytologic subtype, and the expression pattern of typical 
HCC markers. Of note, only one PDX model (C284b) 
lost part of the histologic characteristics (i.e., trabecular 
growth pattern) observed in the originating human 
HCC. This may be due to heterogeneous growth patterns 
in different regions of the same tumor. RNA sequenc-
ing of the HCC PDX tumors and the corresponding 
human HCC biopsies revealed that pathways related 
to angiogenesis and immune cells were generally 
down-regulated in the PDX models, likely a consequence 
of the loss of human immune cells and the presence 
of murine instead of human vasculature in these PDX 
models. By contrast, cell-cycle-related genes were up- 
regulated in the PDX models compared to the biop-
sies, suggesting an enrichment of cancer cells in the 
PDX tumors. Importantly, after accounting for these 
systematic differences, all PDX tumors clustered with 
their corresponding human HCC, demonstrating that 
they recapitulate the tumor-specific gene expression 
profiles. In C284b, the correlation between the human 
HCC and the PDX tumors was weaker than in other 
cases. This is likely explained by the loss of the tra-
becular growth pattern in the PDX tumor and the 
lower tumor content in the biopsy (<30% according 
to WES-based CNA analysis; data not shown(40,41)). 
Furthermore, HCC-specific expression of somatic 
mutations in cancer genes was maintained in the corre-
sponding PDX models. Of note, transcriptome-based 
CNA analysis revealed that the PDX tumors are stable 
over several generations. A recent study questioned the 
ability of cancer PDX models to faithfully recapitulate 
the molecular changes present in the original tumors 
because CNA landscapes of cancer PDX models 
diverge from those of the originating tumors during 
initial transplantation and, to a lesser extent, during 
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passaging.(9) However, HCC-derived data were lim-
ited in their study. In the present study we show that 
the overall pattern of CNAs is largely preserved from 
HCC biopsy to first-generation tumors and that the 
CNA landscape remains stable over 6 generations. We 
observed two cases that showed clear differences from 
HCC biopsy to first-generation tumors. Is this evi-
dence for mouse-specific tumor evolution? We think 
that these genetic differences resulted from intratu-
mor genetic heterogeneity within the original HCC 
tumors rather than the xenografting process. Taken 
together, our results demonstrate that the PDX mod-
els faithfully recapitulate the histopathologic, tran-
scriptomic, and genomic characteristics of the HCC 
tumors from which they were derived.
The diversity of our patient cohort allowed us to 
identify potential determinants of tumor engraft-
ment in mice. Differentiation grade was the major 
 determinant for successful PDX development because 
only poorly differentiated biopsies (Edmondson 
grades III/IV) and those of molecular subclasses 
S1 and S2(26) formed tumors in mice. Accordingly, 
engrafted tumors overexpressed genes related to 
proliferation and epithelial-to-mesenchymal transi-
tion. However, within the group of poorly differenti-
ated HCCs, we could not identify further clinical or 
transcriptomic characteristics affecting engraftment.
Three HCC biopsies resulted in PDX models 
that did not resemble the corresponding HCC. The 
histologic appearance of lymphocytes, strong posi-
tivity for the human B-cell marker CD20, transcrip-
tional up-regulation of immune cell signatures, loss 
of expression of the HCC-specific somatic muta-
tions, and distinct CNA profiles suggest that human 
B-cell lymphomas were formed in these PDX mod-
els. This phenomenon has been described for PDX 
models derived from a number of human cancer 
tissues.(35-38) It has been reported that treatment 
with rituximab, an anti-CD20 monoclonal antibody, 
prevented lymphomatous outgrowth in early passage 
ovarian xenografts.(38) Whether a similar strategy 
would improve the success rate of HCC PDX gen-
eration and prevent lymphomagenesis remains to be 
investigated.
In conclusion, using needle biopsies instead of 
resected specimens allows the generation of PDX 
models from advanced stages of HCC. Our model 
system has a success rate of approximately 20% and 
is currently restricted to Edmondson grades III and 
IV tumors, but within this group, it is representative 
of the entire molecular spectrum of poorly differenti-
ated HCCs. We demonstrated that the PDX tumors 
recapitulate the histopathologic, transcriptomic, and 
genomic features of the original human HCCs, and 
these features remain stable over 6 generations of 
retransplantation. Serial passaging over 6 generations 
allows for the expansion of the tumors from small 
pieces of biopsies into several hundred xenograft- 
carrying mice. Although not suitable for the testing 
of immunotherapy due to the use of immunodefi-
cient mice, we conclude that PDX models from HCC 
needle biopsies fulfill the requirements for preclini-
cal drug development strategies that account for the 
diversity of anticancer drug responses in HCCs.
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